Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Nicergoline from China · 1 trial · 1 indication
MDL is the primary metabolizer of Nicergoline
MDL is the primary metabolizer of Nicergoline
MDL is the primary metabolizer of Nicergoline
| Arm | Type | Description |
|---|---|---|
| Test: Nicergoline manufactured in China | EXPERIMENTAL | - |
| Reference: Nicergoline manufactured in Italy | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Nicergoline from China | DRUG | This is the test arm of China local manufactured Nicergoline |
| Nicergoline from Italy | DRUG | This is the reference arm of Italy originator Nicergoline. |
Inclusion Criteria: Age and Sex: 1. Male and female participants must be 18 to 55 years of age, inclusive, at the time of signing the informed consent document (ICD). • Refer to Appendix 4 for reproductive criteria for male (Section 10.4.1) and female (Section 10.4.2) participants. Type of...
Nicergoline from China is a small molecule drug being studied for pharmacokinetics. It is currently in Phase 1 clinical development. The drug is being investigated in a bioequivalence study to compare a 10 mg tablet manufactured in China with a 10 mg tablet manufactured in Italy under fasted and fed conditions in healthy Chinese participants.
Nicergoline from China is being developed by Pfizer, Inc., which is listed on the stock exchange under the ticker PFE. The drug is currently in Phase 1 clinical development for pharmacokinetics.
Nicergoline from China is in Phase 1 clinical development. It is an investigational drug being studied for pharmacokinetics. The drug has completed one Phase 1 trial, and it is not yet approved by regulatory authorities.
Nicergoline from China has one completed clinical trial, NCT04176367. This was a Phase 1 bioequivalence study comparing a 10 mg tablet manufactured in China with a 10 mg tablet manufactured in Italy under fasted and fed conditions in healthy Chinese participants. The trial enrolled 40 participants and was conducted in China.
Nicergoline from China refers to a specific formulation of nicergoline, a small molecule drug, that is manufactured in China. It is being studied for pharmacokinetics and is currently in Phase 1 clinical development. The drug is being compared to a version manufactured in Italy in a bioequivalence study.